Advanced search
Publication Cover
Expert Review of Vaccines Volume 9, 2010 - Issue 12
Submit an article Journal homepage
631
Views
53
CrossRef citations to date
0
Altmetric
Vaccine Profile

IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine

Mohan Babu Appaiahgari Vaccine and Infectious Disease Research Center, Translational Health Science and Technology Institute, Gurgaon 122 016, India; Vaccine and Infectious Disease Research Center, Translational Health Science and Technology Institute, Gurgaon 122 016, India
&
Sudhanshu Vrati Vaccine and Infectious Disease Research Center, Translational Health Science and Technology Institute, Gurgaon 122 016, India; National Institute of Immunology, New Delhi 110 067, India. [email protected]; National Institute of Immunology, New Delhi 110 067, India. [email protected]
Pages 1371-1384 | Published online: 09 Jan 2014

References

  • Solomon T, Ni H, Beasley DW, Ekkelenkamp M, Cardosa MJ, Barrett AD. Origin and evolution of Japanese encephalitis virus in southeast Asia. J. Virol.77, 3091–3098 (2003).
  • World Health Organization. Japanese encephalitis vaccines. Wkly Epidemiol. Rec.73, 337–344 (1998).
  • Vaughn DW, Hoke CH Jr. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol. Rev.14, 197–221 (1992).
  • Hanna JN, Ritchie SA, Phillips DA et al. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med. J. Aust.165, 256–260 (1996).
  • Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med.10, S98–S109 (2004).
  • Samuel P, Hiriyan J, Gajanana A. Indian Council of Medical Research, New Delhi, India. Japanese encephalitis virus infection in mosquitoes and its epidemiological implications. ICMR Bull.30(4), 37–43 (2000).
  • Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J. Travel Med.16, 217–219 (2009).
  • Fischer M, Lindsey N, Staples JE, Hills S. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.59, 1–27 (2010).
  • Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg. Infect. Dis.15, 1–7 (2009).
  • Chen KM, Tsai HC, Sy CL et al. Clinical manifestations of Japanese encephalitis in southern Taiwan. J. Microbiol. Immunol. Infect.42, 296–302 (2009).
  • Gould EA, Buckley A, Barrett AD, Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J. Gen. Virol.67(Pt 3), 591–595 (1986).
  • Hawkes RA, Roehrig JT, Hunt AR, Moore GA. Antigenic structure of the Murray Valley encephalitis virus E glycoprotein. J. Gen. Virol.69( Pt 5), 1105–1109 (1988).
  • Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol.141, 3606–3610 (1988).
  • Kaur R, Sachdeva G, Vrati S. Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein. J. Infect. Dis.185, 1–12 (2002).
  • Konishi E, Yamaoka M, Khin SW, Kurane I, Takada K, Mason PW. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J. Virol.73, 5527–5534 (1999).
  • Pan CH, Chen HW, Huang HW, Tao MH. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. J. Virol.75, 11457–11463 (2001).
  • Monath TP. Japanese encephalitis vaccines: current vaccines and future prospects. Curr. Top. Microbiol. Immunol.267, 105–138 (2002).
  • Appaiahgari MB, Saini M, Rauthan M, Jyoti A, Vrati S. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect.8, 92–104 (2006).
  • Appaiahgari MB, Vrati S. Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine22, 3669–3675 (2004).
  • Saini M, Vrati S. A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J. Virol.77, 3487–3494 (2003).
  • Bista MB, Banerjee MK, Shin SH et al. Efficacy of single-dose SA14-14-12 vaccine against Japanese encephalitis: a case control study. Lancet358, 791–795 (2001).
  • Jones T. IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection. Curr. Opin. Mol. Ther.11, 90–96 (2009).
  • Guirakhoo F, Zhang ZX, Chambers TJ et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live-attenuated vaccine candidate against Japanese encephalitis. Virology257, 363–372 (1999).
  • Konishi E, Ajiro N, Nukuzuma C, Mason PW, Kurane I. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine21, 3675–3683 (2003).
  • Hoke CH, Nisalak A, Sangawhipa N et al. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med.319, 608–614 (1988).
  • Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J. Infect. Dis.161, 878–882 (1990).
  • Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet337, 1044 (1991).
  • Plesner AM, Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine15, 1239–1243 (1997).
  • Plesner AM, Arlien-Soborg P, Herning M. Neurological complications and Japanese encephalitis vaccination. Lancet348, 202–203 (1996).
  • Sakaguchi M, Nakashima K, Takahashi H, Nakayama T, Fujita H, Inouye S. Anaphylaxis to Japanese encephalitis vaccine. Allergy56, 804–805 (2001).
  • Ni H, Chang GJ, Xie H, Trent DW, Barrett AD. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J. Gen. Virol.76(Pt 2), 409–413 (1995).
  • Yongxin Y, Lee CK, Wood D et al.; World Health Organization. Guidelines for the production and control of Japanese encephalitis vaccine (live) for human use. WHO Technical Report Series910, 67–98 (2002).
  • Liu ZL, Hennessy S, Strom BL et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-12): results of a randomized trial with 26,239 subjects. J. Infect. Dis.176, 1366–1369 (1997).
  • Sohn YM, Tandan JB, Yoksan S, Ji M, Ohrr H. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-12 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine26, 1638–1643 (2008).
  • Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA14-14-12 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case–control study. Lancet366, 1375–1378 (2005).
  • Tandan JB, Ohrr H, Sohn YM et al. Single dose of SA 14-14-12 vaccine provides long-term protection against Japanese encephalitis: a case–control study in Nepalese children 5 years after immunization. Vaccine25, 5041–5045 (2007).
  • Jia L, Wang Z, Yu Y. Protection of SA14-14-12 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses. Chin. Med. J. (Engl.)116, 941–943 (2003).
  • World Health Organization. Global Advisory Committee on vaccine safety, 9–10 June 2005. Wkly Epidemiol. Rec.80(28), 242–243 (2005).
  • Gatchalian S, Yao Y, Zhou B et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live-attenuated Japanese encephalitis SA 14–14–12 vaccine in Philippine infants. Vaccine26, 2234–2241 (2008).
  • Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin Biol. Ther.9, 921–931 (2009).
  • Kaltenbock A, Dubischar-Kastner K, Eder G et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine27, 4483–4489 (2009).
  • Kaltenbock A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine28, 834–839 (2010).
  • Hahn CS, Dalrymple JM, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc. Natl Acad. Sci. USA84, 2019–2023 (1987).
  • Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr. Opin Infect. Dis.18, 387–394 (2005).
  • Martin M, Tsai TF, Cropp B et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet358, 98–104 (2001).
  • Silva ML, Espirito-Santo LR, Martins MA et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol.17, 118–126 (2010).
  • Pulendran B, Miller J, Querec TD et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis.198, 500–507 (2008).
  • Bae HG, Domingo C, Tenorio A et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J. Infect. Dis.197, 1577–1584 (2008).
  • Barrett AD. Current status of flavivirus vaccines. Ann. NY Acad. Sci.951, 262–271 (2001).
  • Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol.73, 3095–3101 (1999).
  • McGee CE, Lewis MG, Claire MS et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J. Infect. Dis.197, 693–697 (2008).
  • Lee E, Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J. Virol.82, 6024–6033 (2008).
  • Charlier N, Molenkamp R, Leyssen P et al. Exchanging the yellow fever virus envelope proteins with Modoc virus prM and E proteins results in a chimeric virus that is neuroinvasive in SCID mice. J. Virol.78, 7418–7426 (2004).
  • Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live-attenuated vaccines against flavivirus infections. Vaccine20, 1004–1018 (2002).
  • Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine28, 632–649 (2010).
  • Nitayaphan S, Grant JA, Chang GJ, Trent DW. Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14-14-12. Virology177, 541–552 (1990).
  • Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J. Virol.75, 934–942 (2001).
  • Monath TP, Arroyo J, Levenbook I et al. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live-attenuated vaccines. J. Virol.76, 1932–1943 (2002).
  • World Health Organization. Requirements for Yellow Fever Vaccine. WHO Technical Report Series 872 [Annex 2]. World Health Organization, Geneva, Switzerland, 30–68 (1998).
  • Monath TP, Myers GA, Beck RA et al. Safety testing for neurovirulence of novel live-attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals33, 131–144 (2005).
  • Monath TP, Soike K, Levenbook I et al. Recombinant, chimaeric live-attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-12) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine17, 1869–1882 (1999).
  • De Groot AS, Martin W, Moise L, Guirakhoo F, Monath T. Analysis of ChimeriVax Japanese encephalitis virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine25, 8077–8084 (2007).
  • Beasley DW, Li L, Suderman MT et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine22, 3722–3726 (2004).
  • Lobigs M, Larena M, Alsharifi M, Lee E, Pavy M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J. Virol.83, 2436–2445 (2009).
  • Dean CH, Alarcon JB, Waterston AM et al. Cutaneous delivery of a live-attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum. Vaccin.1, 106–111 (2005).
  • Monath TP, Guirakhoo F, Nichols R et al. Chimeric live-attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis.188, 1213–1230 (2003).
  • Chuang CK, Chen WJ. Experimental evidence that RNA recombination occurs in the Japanese encephalitis virus. Virology394, 286–297 (2009).
  • Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet363, 2073–2075 (2004).
  • Hombach J, Kurane I, Wood D. Arguments for live flavivirus vaccines. Lancet364, 498–499 (2004).
  • Murphy BR, Blaney JE Jr, Whitehead SS. Arguments for live flavivirus vaccines. Lancet364, 499–500 (2004).
  • de Silva A, Messer W. Arguments for live flavivirus vaccines. Lancet364, 500 (2004).
  • Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am. J. Trop. Med. Hyg.62, 480–484 (2000).
  • Reid M, Mackenzie D, Baron A et al. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am. J. Trop. Med. Hyg.75, 659–663 (2006).
  • Barban V, Girerd Y, Aguirre M et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine25, 2941–2950 (2007).
  • Pugachev KV, Guirakhoo F, Ocran SW et al. High fidelity of yellow fever virus RNA polymerase. J. Virol.78, 1032–1038 (2004).
  • Xie H, Cass AR, Barrett AD. Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations. Virus Res.55, 93–99 (1998).
  • Pugachev KV, Schwaiger J, Brown N et al. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE). Vaccine25, 6661–6671 (2007).
  • McGee CE, Tsetsarkin K, Vanlandingham DL et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J. Infect. Dis.197, 686–692 (2008).
  • Brandler S, Brown N, Ermak TH et al. Replication of chimeric yellow fever virus-dengue serotype 1–4 virus vaccine strains in dendritic and hepatic cells. Am. J. Trop. Med. Hyg.72, 74–81 (2005).
  • Monath TP, Liu J, Kanesa-Thasan N et al. A live-attenuated recombinant West Nile virus vaccine. Proc. Natl Acad. Sci. USA103, 6694–6699 (2006).
  • Monath TP, Levenbook I, Soike K et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol.74, 1742–1751 (2000).
  • Guirakhoo F, Pugachev K, Zhang Z et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol.78, 4761–4775 (2004).
  • Higgs S, Vanlandingham DL, Klingler KA et al. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am. J. Trop. Med. Hyg.75, 986–993 (2006).
  • Johnson BW, Chambers TV, Crabtree MB et al. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am. J. Trop. Med. Hyg.67, 260–265 (2002).
  • Johnson BW, Chambers TV, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am. J. Trop. Med. Hyg.70, 89–97 (2004).
  • Guirakhoo F, Zhang Z, Myers G et al. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J. Virol.78, 9998–10008 (2004).
  • Guirakhoo F, Pugachev K, Arroyo J et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology298, 146–159 (2002).
  • Deauvieau F, Sanchez V, Balas C et al. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1–4. Am. J. Trop. Med. Hyg.76, 144–154 (2007).
  • Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin.2, 60–67 (2006).
  • Guy B, Barban V, Mantel N et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg.80, 302–311 (2009).
  • Monath TP. Prospects for development of a vaccine against the West Nile virus. Ann. NY Acad. Sci.951, 1–12 (2001).
  • Hall RA, Khromykh AA. ChimeriVax-West Nile vaccine. Curr. Opin. Mol. Ther.9, 498–504 (2007).
  • Arroyo J, Miller C, Catalan J et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol.78, 12497–12507 (2004).
  • Rumyantsev AA, Zhang ZX, Gao QS et al. Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus. Virology396, 329–338 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.